VEON’s Kyivstar buys Tabletki.ua for $160M
VEON Ltd., through its subsidiary Kyivstar Group Ltd., has completed the acquisition of 100% of Ukrainian digital healthcare platform Tabletki.ua for USD 160 million, payable in Ukrainian hryvna in Ukraine.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VEON Ltd., through its subsidiary Kyivstar Group Ltd., has completed the acquisition of 100% of Ukrainian digital healthcare platform Tabletki.ua for USD 160 million, payable in Ukrainian hryvna in Ukraine.
Tabletki.ua is a leading Ukrainian platform for finding, comparing, and reserving medicines, partnering with more than 14,000 pharmacies and handling an average of 14 million reservations per month in 2025. Bookings through the platform reached gross merchandise value of UAH 45 billion (USD 1.06 billion) in FY2024 and UAH 57.3 billion (USD 1.19 billion) for the twelve months ending September 30, 2025. Based on unaudited management accounts as of September 30, 2025, Tabletki.ua generated EBITDA of USD 24 million and net profit of USD 20 million, implying a price-to-earnings multiple of 8.0x. The business will join Kyivstar’s broader digital ecosystem, which includes the Helsi e-health platform, Uklon, Kyivstar TV and the MyKyivstar super-app, supporting VEON and Kyivstar’s broader plan to invest USD 1 billion in Ukraine between 2023-2027.
Insights
Profitable healthcare platform acquisition deepens Kyivstar’s digital ecosystem in Ukraine.
Kyivstar has acquired 100% of Tabletki.ua for USD 160 million, adding a scaled, transaction-driven healthcare platform. Tabletki.ua handled about 14 million monthly reservations in 2025 and reached GMV of UAH 57.3 billion (USD 1.19 billion) in the twelve months ending September 30, 2025.
Based on unaudited management accounts as of September 30, 2025, Tabletki.ua delivered EBITDA of USD 24 million and net profit of USD 20 million, implying an 8.0x price-to-earnings multiple. For a digital asset with strong usage metrics, this valuation may appear disciplined, though actual accretion for VEON depends on integration and future performance.
The deal complements Kyivstar’s earlier Helsi acquisition and other digital services, reinforcing its positioning in Ukrainian e-health and consumer digital platforms. Future company communications and financial reports will clarify how Tabletki.ua’s profitability and growth trends contribute to VEON’s consolidated results following closing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What acquisition did VEON (VEON) announce involving Kyivstar and Tabletki.ua?
How large is Tabletki.ua’s business according to the VEON (VEON) filing?
What are Tabletki.ua’s earnings and valuation metrics in the VEON (VEON) disclosure?
How does the Tabletki.ua acquisition fit Kyivstar’s and VEON’s Ukraine strategy?
What services does Tabletki.ua provide, according to VEON (VEON)?
Where can investors find more information on the Tabletki.ua deal from VEON (VEON)?
AI-generated analysis. How Rhea-AI works. Not financial advice.